Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Mónica Gómez-Juárez"'
Autor:
Ainara Achaerandio-de Nova, María D Berenguer-Romero, Syonghyun Nam Cham, Mónica Gómez-Juárez Sango, Sergio Losa-Palacios, Angel Escudero-Jiménez, Manuel Gerónimo-Pardo
Publikováno v:
European Journal of Inflammation, Vol 20 (2022)
Objectives We investigated the effects of repeated intra-articular injections of liquid sevoflurane to articular structures, as this inhalational anesthetic is being repurposed as an antimicrobial agent, which would make sevoflurane a novel alternati
Externí odkaz:
https://doaj.org/article/0662c33d85504d7d94086807ac740338
Autor:
María del Mar Noblejas-López, Cristina Nieto-Jimenez, Miguel Burgos, Mónica Gómez-Juárez, Juan Carlos Montero, Azucena Esparís-Ogando, Atanasio Pandiella, Eva M. Galán-Moya, Alberto Ocaña
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 38, Iss 1, Pp 1-9 (2019)
Abstract Background Triple negative breast cancer (TNBC) is an incurable disease where novel therapeutic strategies are needed. Proteolysis targeting chimeric (PROTAC) are novel compounds that promote protein degradation by binding to an ubiquitin li
Externí odkaz:
https://doaj.org/article/037decabfb344e37b370504e1a55b383
Autor:
María del Mar Noblejas-López, Lucía Gandullo-Sánchez, Eva M. Galán-Moya, Raquel López-Rosa, David Tébar-García, Cristina Nieto-Jiménez, Mónica Gómez-Juárez, Miguel Burgos, Atanasio Pandiella, Alberto Ocaña
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 10, p 5476 (2022)
Cyclin-dependent kinases (CDKs) are a broad family of proteins involved in the cell cycle and transcriptional regulation. In this article, we explore the antitumoral activity of a novel proteolysis-targeting chimera (PROTAC) compound against CDK9. Br
Externí odkaz:
https://doaj.org/article/7a179b3875cc48c09e6d42df7b04d5eb
Autor:
Sergio Losa-Palacios, Manuel Gerónimo-Pardo, Ainara Achaerandio-de Nova, María Dolores Berenguer-Romero, Mónica Gómez-Juárez Sango, Ángel Escudero-Jiménez
Publikováno v:
Laboratory Animals. 55:270-280
Haematogenous models of septic arthritis have some inherent disadvantages, such as the manifestation of arthritis relies on chance, the size of the inoculum is unknown and the number of animals to be studied cannot be reduced because the animals cann
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ainara, Achaerandio-de Nova, Mónica, Gómez-Juárez Sango, Ángel, Escudero-Jiménez, Sergio, Losa-Palacios, María Dolores, Berenguer-Romero, Manuel, Gerónimo-Pardo
Publikováno v:
Laboratory animals. 55(3)
Haematogenous models of septic arthritis have some inherent disadvantages, such as the manifestation of arthritis relies on chance, the size of the inoculum is unknown and the number of animals to be studied cannot be reduced because the animals cann
Autor:
Verónica Corrales-Sánchez, Beatriz Domingo, Miguel Burgos, Cristina Nieto-Jiménez, Atanasio Pandiella, María Del Mar Noblejas-López, Eva María Galán-Moya, Mónica Gómez-Juárez, Maria Granada Picazo-Martinez, Azucena Esparís-Ogando, Juan Carlos Montero, Alberto Ocaña
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
The inhibition of bromo- and extraterminal domains (BET) has shown an anti-proliferative effect in triple negative breast cancer (TNBC). In this article we explore mechanisms of resistance to BET inhibitors (BETi) in TNBC, with the aim of identifying
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e53a7dae6ae1027d407a291914f95e2
http://hdl.handle.net/10261/222915
http://hdl.handle.net/10261/222915
Autor:
Cristina Nieto-Jiménez, Atanasio Pandiella, Juan Carlos Montero, Alberto Ocaña, Mónica Gómez-Juárez, Eva María Galán-Moya, Miguel Burgos, María Del Mar Noblejas-López, Azucena Esparís-Ogando
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
Journal of Experimental & Clinical Cancer Research : CR
Journal of Experimental & Clinical Cancer Research, Vol 38, Iss 1, Pp 1-9 (2019)
instname
Journal of Experimental & Clinical Cancer Research : CR
Journal of Experimental & Clinical Cancer Research, Vol 38, Iss 1, Pp 1-9 (2019)
[Background] Triple negative breast cancer (TNBC) is an incurable disease where novel therapeutic strategies are needed. Proteolysis targeting chimeric (PROTAC) are novel compounds that promote protein degradation by binding to an ubiquitin ligase. I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5055c1f345573b1affebbd795acdc1f9
http://hdl.handle.net/10261/189604
http://hdl.handle.net/10261/189604
Autor:
Veronica, Corrales Sánchez, Cristina, Nieto-Jiménez, José Antonio, Castro-Osma, Fernando, de Andrés, Pedro J, Pacheco-Liñán, Iván, Bravo, Nuria, Rodríguez Fariñas, Enrique, Niza, Elena, Domínguez-Jurado, Agustín, Lara-Sánchez, Ángel, Ríos, Mónica, Gómez Juárez, Juan Carlos, Montero, Atanasio, Pandiella, Alexandr, Shafir, Carlos, Alonso-Moreno, Alberto, Ocaña
Publikováno v:
ACS Omega
Breast cancer is the second leading cause of cancer death worldwide. Despite progress in drug discovery, identification of the correct population is the limiting factor to develop new compounds in the clinical setting. Therefore, the aim of this stud
Autor:
Juan Carlos Montero, Alberto Ocaña, Miguel Burgos, Beatriz Domingo, V. Corrales-Sanchez, Cristina Nieto-Jiménez, Mónica Gómez-Juárez, Javier Pérez-Peña, Atanasio Pandiella, M.D.M. Noblejas López, Eva María Galán-Moya
Publikováno v:
Annals of Oncology. 30:v99
Background Novel therapeutic strategies are needed for the treatment of triple negative breast cancer (TNBC). Inhibition of bromo and extraterminal domains (BET) has shown an anti-proliferative effect in TNBC as well as a synergistic interaction with